Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin's Lymphoma

Phase 2TerminatedNCT00006478

University of Nebraska19 enrolled

Overview

RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to kill cancer cells. Vaccine therapy may be an effective treatment for non-Hodgkin's lymphoma. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy following chemotherapy and peripheral stem cell transplantation in treating patients who have non-Hodgkin's lymphoma.

OBJECTIVES: * Determine the humoral and cellular immune responses in patients with follicular non-Hodgkin's lymphoma treated with autologous lymphoma-derived idiotype vaccine with keyhole limpet hemocyanin plus sargramostim (GM-CSF). * Determine the safety and toxicity of this regimen in these patients in the post-transplant setting. * Determine the changes in quantitative bcl-2 in the blood and bone marrow of these patients before and at various times after the series of idiotype vaccines. OUTLINE: Vaccinations begin at day 100 or up to 6 months after hematopoietic stem cell transplantation. Patients receive autologous lymphoma-derived idiotype vaccine plus keyhole limpet hemocyanin subcutaneously (SC) on day 1. Sargramostim (GM-CSF) SC is administered on days 1-4. Treatment repeats every 4 weeks for 4 doses, followed 12 weeks later by the fifth and final dose. Patients are followed every 3 months for 2 years, every 6 months for 2 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Lymphoma

Interventions

autologous tumor cell vaccineBIOLOGICAL

keyhole limpet hemocyaninBIOLOGICAL

sargramostimBIOLOGICAL

adjuvant therapyPROCEDURE

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Over 19 years of age * Histologically proven grade I, II, or III follicular non-Hodgkin's lymphoma that failed induction therapy * Minimal disease state at day 100 to 6 months post-transplantatio * Lymph nodes smaller than 2 centimeters (cm) * Less than 20% bone marrow involvement with lymphoma * Uncertain complete remission, defined by greater than 75% reduction in the size of the pre-transplantation mass not representing active disease * Tissue sample safely accessible by biopsy, needle aspiration, or phlebotomy o Must have adequate circulating lymphoma cells * Karnofsky greater than 70% * Absolute neutrophil count greater than 1,000/mm\^3 (No restrictions if study vaccine administered at 6 months after transplantation) * CD4+ count greater than 200/microliter (No restrictions if study vaccine administered at 6 months after transplantation) * Bilirubin less than 2.0 mg/dL (unless due to lymphomatous involvement) * Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) less than 2 times normal (unless due to lymphomatous involvement) * Creatinine no greater than 2.0 mg/dL * Fertile patients must use effective contraception during and for 6 months after study participation Exclusion Criteria: * Previously received no more than 2 high-dose chemotherapies before hematopoietic stem cell transplantation * Not pregnant or nursing/negative pregnancy test

Locations (1)

University of Nebraska Medical Center

Omaha, Nebraska, United States

Outcomes

Primary Outcomes

Number of Participants With Humoral and Cellular Immune Response

evaluate the humoral immune responses and cellular immune responses to idiotype vaccine with KLH and GM-CSF adjuvant given to patients with follicular lymphoma following high-dose chemotherapy and autologous stem cell transplantation

Time frame: immune responses will be obtained prior to first immunization (baseline), prior to the 5th, 6th, 7th immunization series and 2 weeks following administration of the 7th immunization series. And then obtained annually until disease progression

Secondary Outcomes

Safety of Idiotype Vaccine

To evaluate the safety of idiotype vaccine with KLH and GM-CSF adjuvant in the post-transplant setting

Time frame: At each immunization and at study completion

Toxicity of Idiotype Vaccine

To evaluate the toxicity of idiotype vaccine with KLH and GM-CSF adjuvant in the post-transplant setting

Time frame: At each immunization and at study completion

Changes in Quantitative Bcl-2

To evaluate changes in quantitative bcl-2 of the blood and bone marrow prior to and at various time points following the series of idiotype vaccines.

Time frame: 1 year post transplant evaluation and then annually until disease progression

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.